Bassem I Yamout
Overview
Explore the profile of Bassem I Yamout including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
37
Citations
355
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Roos I, Sharmin S, Malpas C, Ozakbas S, Lechner-Scott J, Hodgkinson S, et al.
Mult Scler
. 2024 Aug;
30(9):1163-1175.
PMID: 39087208
Background: Comparisons between cladribine and other potent immunotherapies for multiple sclerosis (MS) are lacking. Objectives: To compare the effectiveness of cladribine against fingolimod, natalizumab, ocrelizumab and alemtuzumab in relapsing-remitting MS....
2.
Spelman T, Simoneau G, Hyde R, Kuhelj R, Alroughani R, Ozakbas S, et al.
Neurology
. 2024 Mar;
102(7):e208114.
PMID: 38447093
Background And Objectives: Patients with pediatric-onset multiple sclerosis (POMS) typically experience higher levels of inflammation with more frequent relapses, and though patients with POMS usually recover from relapses better than...
3.
Yamout B, Viswanathan S, Laurson-Doube J, Sokhi D
Mult Scler
. 2023 Oct;
30(1):3-6.
PMID: 37850437
No abstract available.
4.
Roos I, Malpas C, Leray E, Casey R, Horakova D, Kubala Havrdova E, et al.
Neurology
. 2022 Aug;
99(17):e1926-e1944.
PMID: 35977837
Background And Objectives: To evaluate the rate of return of disease activity after cessation of multiple sclerosis (MS) disease-modifying therapy. Methods: This was a retrospective cohort study from 2 large...
5.
Vitkova M, Diouf I, Malpas C, Horakova D, Kubala Havrdova E, Patti F, et al.
Neurology
. 2022 Apr;
98(24):e2401-e2412.
PMID: 35410900
Background And Objectives: The severity of multiple sclerosis (MS) varies widely among individuals. Understanding the determinants of this heterogeneity will help clinicians optimize the management of MS. The aim of...
6.
Yamout B, Zakaria M, Inshasi J, Al-Jumah M, Zeineddine M, Dahdaleh M, et al.
Mult Scler Relat Disord
. 2021 Sep;
56:103225.
PMID: 34479111
Patients with multiple sclerosis (MS) should be vaccinated against COVID-19. All COVID-19 vaccines are effective and do not appear to carry any additional risk for patients with MS. Patients with...
7.
Yeh W, Widyastuti P, van der Walt A, Stankovich J, Havrdova E, Horakova D, et al.
Neurology
. 2021 Apr;
96(24):e2989-e3002.
PMID: 33879599
Objective: To investigate pregnancy-related disease activity in a contemporary multiple sclerosis (MS) cohort. Methods: Using data from the MSBase Registry, we included pregnancies conceived after 31 Dec 2010 from women...
8.
Le M, Malpas C, Sharmin S, Horakova D, Havrdova E, Trojano M, et al.
Mult Scler
. 2020 Jun;
27(5):755-766.
PMID: 32538713
Background: Cerebellar and brainstem symptoms are common in early stages of multiple sclerosis (MS) yet their prognostic values remain unclear. Objective: The aim of this study was to investigate long-term...
9.
Yamout B, Assaad W, Tamim H, Mrabet S, Goueider R
Mult Scler J Exp Transl Clin
. 2020 Jan;
6(1):2055217319841881.
PMID: 31984137
The Middle East North Africa (MENA) region falls in the low-to-moderate multiple sclerosis (MS) prevalence zone, with prevalence rates slightly lower than Southern Europe but much higher than sub-Saharan Africa....
10.
Zeineddine M, Yamout B
Mult Scler J Exp Transl Clin
. 2020 Jan;
6(1):2055217319848466.
PMID: 31976080
Multiple sclerosis was long considered a relatively rare entity in the Middle East, but research over the past 10 years and the publication of the Middle East North Africa Committee...